Fig. 2
From: Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth
Hino/iron complex Fe(hino)3 induces cell death in TNBCs. A Cell viability in MDA-MB-231 treated with different concentrations of Hino and FAC for 24 h. B, C Propidium iodide (PI) staining (B) and lactate dehydrogenase (LDH) release (C) in MDA-MB-231 treated with Hino (10 µM), FAC (5 µM), or/and deferiprone (DFP as an iron chelator) (10 µM) for 24 h. D The structure of Hino, DFP, and Hino/iron complex Fe(hino)3 [9]. E Colors and UV/vis absorption spectra (260–700 nm range) of Hino, FeCl3 (1 mM), a mixture of Hino (3 mM) and FeCl3 (1 mM), and Fe(hino)3 (1 mM). F Colors and UV/vis absorption spectra (260–700 nm range) of the cell lysate of MDA-MB-231 treated with Hino (100 µM), FAC (33 µM), and Hino (100 µM) + FAC (33 µM) for 12 h. G Cell viability of MDA-MB-231 treated with different concentrations of Hino, Hino:FAC (3:1), or Fe(hino)3 for 24 h. The number of seeded cells is 10,000 per well. H Cell morphology, LDH release, cell number of MDA-MB-231 cells treated with Hino (15 µM) or Fe(hino)3 (5 µM) for 24 h. I Cell viability of MDA-MB-231 or 4T-1 cells treated with different concentrations of Fe(hino)3 for 24 h. *: compared to the untreated MDA-MB-231 cells; #: compared to the untreated 4T-1 cells. ***, p < 0.001; #, p < 0.05